Alzheimer’s cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans

Table 3 ROC parameters for CSF biomarkers measured by different immunoassay platforms to discriminate participants with amyloid-PET positivity from those with amyloid-PET negativity

Assay platforms	Parameters	Aβ₄₂	Aβ₄₀	T-tau	P-tau	T-tau/Aβ₄₂	P-tau/Aβ₄₂	Aβ₄₂/Aβ₄₀
Luminex-AlzBio3	n*	125	–	124	125	124	125
	ROC AUC	0.897	–	0.694	0.810	0.852	0.892	–
	Cut-off value	380.6 pg/mL	–	75.6 pg/mL	21.02 pg/mL	0.133	0.045	–
	PPA (%)	79.5	–	43.6	74.4	79.5	87.2	–
	NPA (%)	93.0	–	97.7	81.4	92.9	88.4	–
INNOTEST	n	123	123	115	109	115	109	123
	ROC AUC	0.860	n.s.	0.803	0.717	0.884	0.846	0.896
	Cut-off value	478.3 pg/mL	–	247.3 pg/mL	46.3 pg/mL	0.484	0.079	0.091
	PPA (%)	76.9	–	77.8	73.5	83.3	80.0	89.7
	NPA (%)	94.1	–	73.4	60.8	94.9	87.8	83.3
Lumipulse	n	123	126	123	123	123	123	123
	ROC AUC	0.857	n.s.	0.791	0.839	0.842	0.840	0.856
	Cut-off value	642.1 pg/mL	–	337 pg/mL	36.0 pg/mL	0.315	0.051	0.060
	PPA (%)	79.5	–	59.0	79.5	84.6	84.6	84.6
	NPA (%)	88.1	–	89.3	78.6	88.1	92.9	91.7

ROC AUC area under the receiver operating characteristic curve, PPA positive percent agreement, NPA negative percent agreement
*T-tau measured by Luminex of one sample and t-tau and p-tau measured using INNOTEST kits of 10 and 16 samples respectively were excluded following acceptance criteria of SOP, and two samples could not be measured due to loss of samples. 3 AD patients with Aβ-PET negative and normal CSF Aβ42 level were excluded to follow the A/T/N criteria for biological definition of AD

ISSN: 1758-9193